High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma
Open Access
Abstract
Glioblastoma (GB) is one of the deadliest human cancers. Many GB patients do not respond to treatment, and inevitably die within a median of 15–18 months post-diagnosis, highlighting the need for reliable biomarkers to aid clinical management and treatment evaluation. The GB microenvironment holds tremendous potential as a source of biomarkers; several proteins such as MMP-2, MMP-9, YKL40, and VEGFA have been identified as being differentially expressed in GB patient samples. Still to date, none of these proteins have been translated into relevant clinical biomarkers. This study evaluated the expression of MMP-2, MMP-9, YKL40, and VEGFA in a series of GBs and their impact on patient outcome. High levels of VEGFA expression were significantly associated with improved progression-free survival after bevacizumab treatment, thus having potential as a tissue biomarker for predicting patients’ response to bevacizumab. Noteworthily, VEGFA expression was not associated with patient outcome after temozolomide treatment. To a lesser extent, YKL40 also provided significant information regarding the extent of bevacizumab treatment. This study highlights the importance of studying secretome-associated proteins as GB biomarkers and identifies VEGFA as a promising marker for predicting response to bevacizumab.Keywords
Funding Information
- FEDER—Fundo Europeu de Desenvolvimento Regional funds (PTDC/BIA-MIC/28779/2017, UID/BIM/04293/2019, NORTE-01-0145-FEDER-000051, NORTE-01-0145-FEDER-072678)
- Portuguese funds (PTDC/BIA-MIC/28779/2017, UID/BIM/04293/2019, NORTE-01-0145-FEDER-000051, NORTE-01-0145-FEDER-072678)
- Norte Portugal Regional Operational Programme (NORTE 2020) (PTDC/BIA-MIC/28779/2017, UID/BIM/04293/2019, NORTE-01-0145-FEDER-000051, NORTE-01-0145-FEDER-072678)
- European Regional Development Fund (ERDF) (PTDC/BIA-MIC/28779/2017, UID/BIM/04293/2019, NORTE-01-0145-FEDER-000051, NORTE-01-0145-FEDER-072678)
This publication has 74 references indexed in Scilit:
- VEGF Promotes Proliferation of Human Glioblastoma Multiforme Stem‐Like Cells through VEGF Receptor 2The Scientific World Journal, 2013
- Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microgliaNeuro-Oncology, 2011
- Expression of VEGF and MMP-9 and MRI imaging changes in cerebral gliomaOncology Letters, 2011
- Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of GlioblastomaJournal of Biological Chemistry, 2011
- Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factorNeuro-Oncology, 2010
- BevacizumabThe Oncologist, 2010
- High-grade glioma before and after treatment with radiation and Avastin: Initial observationsNeuro-Oncology, 2008
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomasNeuro-Oncology, 2008
- The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro-Oncology, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005